{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:42:35Z","timestamp":1792806155635,"version":"4.5.0"},"reference-count":39,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Fatigue after aneurysmal subarachnoid hemorrhage (aSAH) is common and usually long-lasting, and it has a considerable negative impact on health-related quality of life (HRQOL), social functioning, and the ability to return to work (RTW). No effective treatment exists. The dopaminergic regulator (\u2212)-OSU6162 has shown promising results regarding the mitigation of fatigue in various neurological diseases, and therefore the authors aimed to investigate the efficacy of (\u2212)-OSU6162 in alleviating fatigue and other sequelae after aSAH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>A double-blind, randomized, placebo-controlled, single-center trial was performed in which 96 participants with post-aSAH fatigue were administered 30\u201360 mg\/day of (\u2212)-OSU6162 or placebo over a period of 12 weeks. Efficacy was assessed using the Fatigue Severity Scale (FSS), the Mental Fatigue Scale (MFS), the Beck Anxiety Inventory (BAI), the Beck Depression Inventory II (BDI-II), the SF-36 questionnaire, and a neuropsychological test battery. Assessments were performed at baseline, after 1, 4, 8, and 12 weeks of treatment, and at follow-up, 8 weeks after treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The 96 participants with post-aSAH fatigue were randomized to treatment with (\u2212)-OSU6162 (n = 49) or placebo (n = 47). The FSS, MFS, and BDI scores improved significantly in both groups after 12 weeks of treatment, whereas the BAI scores improved in the placebo group only. HRQOL improved significantly in the SF-36 domain \u201cVitality\u201d in both groups. Neuropsychological test performances were within the normal range at baseline and not affected by treatment. The FSS score was distinctly improved in patients with complete RTW upon treatment with (\u2212)-OSU6162. Concomitant use of antidepressants improved the efficacy of (\u2212)-OSU6162 on the FSS score at week 1 beyond the placebo response, and correspondingly the use of beta- or calcium-channel blockers improved the (\u2212)-OSU6162 efficacy beyond the placebo response in MFS scores at week 4 of treatment. There was a significant correlation between improvement in FSS, BAI, and BDI scores and the plasma concentration of (\u2212)-OSU6162 at the dose of 60 mg\/day. No serious adverse events were attributable to the treatment, but dizziness was reported more often in the (\u2212)-OSU6162 group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Fatigue and other sequelae after aSAH were similarly alleviated by treatment with (\u2212)-OSU6162 and placebo. (\u2212)-OSU6162 improved fatigue, as measured with the FSS score, significantly in patients with complete RTW. There seemed to be synergetic effects of (\u2212)-OSU6162 and medications interfering with dopaminergic pathways that should be explored further. The strong placebo response may be exploited in developing nonpharmacological treatment programs for post-aSAH fatigue.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3171\/2021.7.jns211305","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T16:34:41Z","timestamp":1636130081000},"page":"1705-1715","source":"Crossref","is-referenced-by-count":6,"title":["(\u2212)-OSU6162 in the treatment of fatigue and other sequelae after aneurysmal subarachnoid hemorrhage: a double-blind, randomized, placebo-controlled study"],"prefix":"10.3171","volume":"136","author":[{"given":"Elin","family":"Western","sequence":"first","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Oslo University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonje Haug","family":"Nordenmark","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Oslo University Hospital;"},{"name":"Department of Psychology, University of Oslo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilhelm","family":"Sorteberg","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Oslo University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Sorteberg","sequence":"additional","affiliation":[{"name":"KTH Royal Institute of Technology, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Karic","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Oslo University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Sorteberg","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Oslo University Hospital;"},{"name":"Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Norway; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"issue":"11","key":"b1","series-title":"Eur J Neurol","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/ene.13723","article-title":"Mental versus physical fatigue after subarachnoid hemorrhage: differential associations with outcome","volume":"25","author":"Buunk AM","year":"2018","unstructured":"Buunk AM, Groen RJM, Wijbenga RA, Ziengs AL, Metzemaekers JDM, van Dijk JMC, Spikman JM. Mental versus physical fatigue after subarachnoid hemorrhage: differential associations with outcome. Eur J Neurol. 2018;25(11):1313\u2013e113.2992448110.1111\/ene.13723"},{"key":"b2","series-title":"World Neurosurg","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/j.wneu.2021.03.148","article-title":"Neurological outcome, mental fatigue, and occurrence of aneurysms >15 years after aneurysmal subarachnoid hemorrhage","volume":"151","author":"Samuelsson J","year":"2021","unstructured":"Samuelsson J, Jakobsson H, Rentzos A, Jakola AS, Nilsson D. Neurological outcome, mental fatigue, and occurrence of aneurysms >15 years after aneurysmal subarachnoid hemorrhage. World Neurosurg. 2021;151:e122\u2013e127.3383161110.1016\/j.wneu.2021.03.148"},{"issue":"12","key":"b3","series-title":"Acta Neurochir (Wien)","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1007\/s00701-020-04538-9","article-title":"Prevalence and predictors of fatigue after aneurysmal subarachnoid hemorrhage","volume":"162","author":"Western E","year":"2020","unstructured":"Western E, Sorteberg A, Brunborg C, Nordenmark TH. Prevalence and predictors of fatigue after aneurysmal subarachnoid hemorrhage. Acta Neurochir (Wien). 2020;162(12):3107\u20133116.10.1007\/s00701-020-04538-932809068"},{"issue":"5","key":"b4","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.3171\/2019.1.JNS183168","article-title":"The post-aSAH syndrome: a self-reported cluster of symptoms in patients with aneurysmal subarachnoid hemorrhage","volume":"132","author":"Haug Nordenmark T","year":"2019","unstructured":"Haug Nordenmark T, Karic T, R\u00f8e C, Sorteberg W, Sorteberg A. The post-aSAH syndrome: a self-reported cluster of symptoms in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg. 2019;132(5):1556\u20131565.10.3171\/2019.1.JNS183168"},{"issue":"6","key":"b5","series-title":"J Neurol","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00415-010-5891-y","article-title":"Predicting fatigue 1 year after aneurysmal subarachnoid hemorrhage","volume":"258","author":"Passier PE","year":"2011","unstructured":"Passier PE, Post MW, van Zandvoort MJ, Rinkel GJ, Lindeman E, Visser-Meily JM. Predicting fatigue 1 year after aneurysmal subarachnoid hemorrhage. J Neurol. 2011;258(6):1091\u20131097.2120705010.1007\/s00415-010-5891-y"},{"issue":"8","key":"b6","series-title":"J Neurol Neurosurg Psychiatry","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1136\/jnnp.2002.000414","article-title":"Psychosocial outcomes at 18 months after good neurological recovery from aneurysmal subarachnoid haemorrhage","volume":"75","author":"Powell J","year":"2004","unstructured":"Powell J, Kitchen N, Heslin J, Greenwood R. Psychosocial outcomes at 18 months after good neurological recovery from aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 2004;75(8):1119\u20131124.1525821210.1136\/jnnp.2002.000414"},{"issue":"4","key":"b7","series-title":"J Psychosom Res","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jpsychores.2011.12.008","article-title":"Fatigue after subarachnoid haemorrhage: a systematic review","volume":"72","author":"Kutlubaev MA","year":"2012","unstructured":"Kutlubaev MA, Barugh AJ, Mead GE. Fatigue after subarachnoid haemorrhage: a systematic review. J Psychosom Res. 2012;72(4):305\u2013310.2240522610.1016\/j.jpsychores.2011.12.008"},{"issue":"9","key":"b8","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1161\/STROKEAHA.116.014327","article-title":"Antidepressant use after aneurysmal subarachnoid hemorrhage: a population-based case-control study","volume":"47","author":"Huttunen J","year":"2016","unstructured":"Huttunen J, Lindgren A, Kurki MI, Huttunen T, Fr\u00f6sen J, von Und Zu Fraunberg M,  Antidepressant use after aneurysmal subarachnoid hemorrhage: a population-based case-control study. Stroke. 2016;47(9):2242\u20132248.2748616710.1161\/STROKEAHA.116.014327"},{"issue":"1","key":"b9","series-title":"Neurosurgery","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1227\/01.NEU.0000097198.94828.E1","article-title":"Anxiety and depression after spontaneous subarachnoid hemorrhage","volume":"54","author":"Morris PG","year":"2004","unstructured":"Morris PG, Wilson JT, Dunn L. Anxiety and depression after spontaneous subarachnoid hemorrhage. Neurosurgery. 2004;54(1):47\u201354.1468354010.1227\/01.NEU.0000097198.94828.E1"},{"issue":"4","key":"b10","series-title":"Neurosurgery","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1097\/00006123-199810000-00030","article-title":"Too little, too late: does tirilazad mesylate reduce fatigue after subarachnoid hemorrhage?","volume":"43","author":"Ogden JA","year":"1998","unstructured":"Ogden JA, Mee EW, Utley T. Too little, too late: does tirilazad mesylate reduce fatigue after subarachnoid hemorrhage?. Neurosurgery. 1998;43(4):782\u2013787.976630410.1097\/00006123-199810000-00030"},{"key":"b11","series-title":"Front Neurol","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3389\/fneur.2015.00052","article-title":"The dopamine imbalance hypothesis of fatigue in multiple sclerosis and other neurological disorders","volume":"6","author":"Dobryakova E","year":"2015","unstructured":"Dobryakova E, Genova HM, DeLuca J, Wylie GR. The dopamine imbalance hypothesis of fatigue in multiple sclerosis and other neurological disorders. Front Neurol. 2015;6:52.2581497710.3389\/fneur.2015.00052"},{"issue":"9413","key":"b12","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S0140-6736(04)15794-2","article-title":"Fatigue in neurological disorders","volume":"363","author":"Chaudhuri A","year":"2004","unstructured":"Chaudhuri A, Behan PO. Fatigue in neurological disorders. Lancet. 2004;363(9413):978\u2013988.1504396710.1016\/S0140-6736(04)15794-2"},{"issue":"11","key":"b13","series-title":"J Neural Transm (Vienna)","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s00702-011-0704-8","article-title":"I. In vivo evidence for partial agonist effects of (-)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors","volume":"118","author":"Carlsson ML","year":"2011","unstructured":"Carlsson ML, Burstein ES, Kloberg A, Hansson S, Schedwin A, Nilsson M,  I. In vivo evidence for partial agonist effects of (-)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors. J Neural Transm (Vienna). 2011;118(11):1511\u20131522.10.1007\/s00702-011-0704-821874578"},{"issue":"5","key":"b14","series-title":"Acta Neuropsychiatr","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1601-5215.2012.00678.x","article-title":"Placebo-controlled cross-over study of the monoaminergic stabiliser (-)-OSU6162 in mental fatigue following stroke or traumatic brain injury","volume":"24","author":"Johansson B","year":"2012","unstructured":"Johansson B, Carlsson A, Carlsson ML, Karlsson M, Nilsson MK, Nordquist-Brandt E, R\u00f6nnb\u00e4ck L. Placebo-controlled cross-over study of the monoaminergic stabiliser (-)-OSU6162 in mental fatigue following stroke or traumatic brain injury. Acta Neuropsychiatr. 2012;24(5):266\u2013274.10.1111\/j.1601-5215.2012.00678.x"},{"issue":"2","key":"b15","series-title":"J Head Trauma Rehabil","doi-asserted-by":"publisher","first-page":"E46","DOI":"10.1097\/HTR.0000000000000236","article-title":"The effects of (-)-OSU6162 on chronic fatigue in patients with traumatic brain injury: a randomized controlled trial","volume":"32","author":"Berginstr\u00f6m N","year":"2017","unstructured":"Berginstr\u00f6m N, Nordstr\u00f6m P, Schuit R, Nordstr\u00f6m A. The effects of (-)-OSU6162 on chronic fatigue in patients with traumatic brain injury: a randomized controlled trial. J Head Trauma Rehabil. 2017;32(2):E46\u2013E54.2712029210.1097\/HTR.0000000000000236"},{"issue":"6","key":"b16","series-title":"Acta Neuropsychiatr","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1017\/neu.2020.22","article-title":"Effect of the monoaminergic stabiliser (-)-OSU6162 on mental fatigue following stroke or traumatic brain injury","volume":"32","author":"Nilsson MKL","year":"2020","unstructured":"Nilsson MKL, Johansson B, Carlsson ML, Schuit RC, R\u00f6nnb\u00e4ck L. Effect of the monoaminergic stabiliser (-)-OSU6162 on mental fatigue following stroke or traumatic brain injury. Acta Neuropsychiatr. 2020;32(6):303\u2013312.10.1017\/neu.2020.22"},{"issue":"4","key":"b17","series-title":"Brain Behav","doi-asserted-by":"publisher","first-page":"e02040","DOI":"10.1002\/brb3.2040","article-title":"Open-label study with the monoamine stabilizer (-)-OSU6162 in myalgic encephalomyelitis\/chronic fatigue syndrome","volume":"11","author":"Haghighi S","year":"2021","unstructured":"Haghighi S, Forsmark S, Zachrisson O, Carlsson A, Nilsson MKL, Carlsson ML,  Open-label study with the monoamine stabilizer (-)-OSU6162 in myalgic encephalomyelitis\/chronic fatigue syndrome. Brain Behav. 2021;11(4):e02040.3352891110.1002\/brb3.2040"},{"issue":"6","key":"b18","series-title":"Acta Neurol Scand","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/ane.13007","article-title":"Open study with (-)-OSU6162 in multiple sclerosis-related fatigue","volume":"138","author":"Haghighi S","year":"2018","unstructured":"Haghighi S, Forsmark S, Carlsson A, Nilsson MKL, Carlsson ML, Schuit RC, Gottfries CG. Open study with (-)-OSU6162 in multiple sclerosis-related fatigue. Acta Neurol Scand. 2018;138(6):482\u2013489.3013278610.1111\/ane.13007"},{"issue":"3","key":"b19","series-title":"Acta Neuropsychiatr","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1017\/neu.2017.35","article-title":"A randomised controlled trial of the monoaminergic stabiliser (-)-OSU6162 in treatment of myalgic encephalomyelitis\/chronic fatigue syndrome","volume":"30","author":"Nilsson MKL","year":"2018","unstructured":"Nilsson MKL, Zachrisson O, Gottfries CG, Matousek M, Peilot B, Forsmark S,  A randomised controlled trial of the monoaminergic stabiliser (-)-OSU6162 in treatment of myalgic encephalomyelitis\/chronic fatigue syndrome. Acta Neuropsychiatr. 2018;30(3):148\u2013157.2921256210.1017\/neu.2017.35"},{"issue":"3","key":"b20","series-title":"J Clin Pharmacol","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1177\/0091270003262792","article-title":"Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers","volume":"44","author":"Rodr\u00edguez CA","year":"2004","unstructured":"Rodr\u00edguez CA, Azie NE, Adams G, Donaldson K, Francom SF, Staton BA, Bombardt PA. Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers. J Clin Pharmacol. 2004;44(3):276\u2013283.1497330810.1177\/0091270003262792"},{"issue":"2","key":"b21","series-title":"Scand J Public Health","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/14034940410028406","article-title":"Fatigue in the general population: a translation and test of the psychometric properties of the Norwegian version of the fatigue severity scale","volume":"33","author":"Lerdal A","year":"2005","unstructured":"Lerdal A, Wahl A, Rust\u00f8en T, Hanestad BR, Moum T. Fatigue in the general population: a translation and test of the psychometric properties of the Norwegian version of the fatigue severity scale. Scand J Public Health. 2005;33(2):123\u2013130.1582397310.1080\/14034940410028406"},{"key":"b22","article-title":"European Medicines Agency. Good Clinical Practice (GCP)","unstructured":"European Medicines Agency. Good Clinical Practice (GCP). Accessed August 6, 2021.https:\/\/www.ema.europa.eu\/en\/ich-e6-r2-good-clinical-practice"},{"issue":"2","key":"b23","series-title":"Neuropsychopharmacology","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/npp.2014.195","article-title":"The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2\/D3 receptors: an [(11)C]raclopride PET study in healthy human subjects","volume":"40","author":"Tolboom N","year":"2015","unstructured":"Tolboom N, Berendse HW, Leysen JE, Yaqub M, van Berckel BN, Schuit RC,  The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2\/D3 receptors: an [(11)C]raclopride PET study in healthy human subjects. Neuropsychopharmacology. 2015;40(2):472\u2013479.10.1038\/npp.2014.195"},{"issue":"7","key":"b24","series-title":"Brain Behav","doi-asserted-by":"publisher","first-page":"e01303","DOI":"10.1002\/brb3.1303","article-title":"Mental fatigue assessment may add information after aneurysmal subarachnoid hemorrhage","volume":"9","author":"S\u00f6rbo A","year":"2019","unstructured":"S\u00f6rbo A, Eiving I, L\u00f6whagen Hend\u00e9n P, Naredi S, Ljungqvist J, Odenstedt Herg\u00e8s H. Mental fatigue assessment may add information after aneurysmal subarachnoid hemorrhage. Brain Behav. 2019;9(7):e01303.3111235210.1002\/brb3.1303"},{"issue":"1","key":"b25","series-title":"Brain Inj","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3109\/02699050903452961","article-title":"A self-assessment questionnaire for mental fatigue and related symptoms after neurological disorders and injuries","volume":"24","author":"Johansson B","year":"2010","unstructured":"Johansson B, Starmark A, Berglund P, R\u00f6dholm M, R\u00f6nnb\u00e4ck L. A self-assessment questionnaire for mental fatigue and related symptoms after neurological disorders and injuries. Brain Inj. 2010;24(1):2\u201312.2000147810.3109\/02699050903452961"},{"issue":"6","key":"b26","series-title":"J Consult Clin Psychol","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1037\/0022-006X.56.6.893","article-title":"An inventory for measuring clinical anxiety: psychometric properties","volume":"56","author":"Beck AT","year":"1988","unstructured":"Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56(6):893\u2013897.320419910.1037\/0022-006X.56.6.893"},{"key":"b27","article-title":"Beck Depression Inventory Manual","author":"Beck AT","year":"1996","unstructured":"Beck AT, Steer RA, Brown GK. Beck Depression Inventory Manual. 2nd ed. Psychological Corporation;1996."},{"issue":"6","key":"b28","series-title":"Med Care","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware JE Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473\u2013483.159391410.1097\/00005650-199206000-00002"},{"issue":"1","key":"b29","series-title":"Health Qual Life Outcomes","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12955-017-0625-9","article-title":"Measurement properties and normative data for the Norwegian SF-36: results from a general population survey","volume":"15","author":"Garratt AM","year":"2017","unstructured":"Garratt AM, Stavem K. Measurement properties and normative data for the Norwegian SF-36: results from a general population survey. Health Qual Life Outcomes. 2017;15(1):51.2829229210.1186\/s12955-017-0625-9"},{"issue":"12","key":"b30","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1161\/01.STR.19.12.1497","article-title":"Recovery of motor function after stroke","volume":"19","author":"Bonita R","year":"1988","unstructured":"Bonita R, Beaglehole R. Recovery of motor function after stroke. Stroke. 1988;19(12):1497\u20131500.320150810.1161\/01.STR.19.12.1497"},{"issue":"5","key":"b31","series-title":"Acta Neuropsychiatr","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1017\/neu.2014.16","article-title":"Tolerability and efficacy of the monoaminergic stabilizer (-)-OSU6162 (PNU-96391A) in Huntington\u2019s disease: a double-blind cross-over study","volume":"26","author":"Kloberg A","year":"2014","unstructured":"Kloberg A, Constantinescu R, Nilsson MK, Carlsson ML, Carlsson A, Wahlstr\u00f6m J, Haghighi S. Tolerability and efficacy of the monoaminergic stabilizer (-)-OSU6162 (PNU-96391A) in Huntington\u2019s disease: a double-blind cross-over study. Acta Neuropsychiatr. 2014;26(5):298\u2013306.2524175810.1017\/neu.2014.16"},{"issue":"4","key":"b32","series-title":"J Psychiatry Neurosci","first-page":"252","article-title":"The therapeutic role of 5-HT1A and 5-HT2A receptors in depression","volume":"29","author":"Celada P","year":"2004","unstructured":"Celada P, Puig M, Amarg\u00f3s-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci. 2004;29(4):252\u2013265.15309042"},{"issue":"1","key":"b33","series-title":"Synapse","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/syn.20574","article-title":"Selective serotonin reuptake inhibitor (SSRI) modulation of striatal dopamine measured with [11C]-raclopride and positron emission tomography","volume":"63","author":"Smith GS","year":"2009","unstructured":"Smith GS, Ma Y, Dhawan V, Chaly T, Eidelberg D. Selective serotonin reuptake inhibitor (SSRI) modulation of striatal dopamine measured with [11C]-raclopride and positron emission tomography. Synapse. 2009;63(1):1\u20136.1892565510.1002\/syn.20574"},{"issue":"2","key":"b34","series-title":"J Neurochem","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/jnc.13125","article-title":"Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat","volume":"134","author":"Bhide N","year":"2015","unstructured":"Bhide N, Lindenbach D, Barnum CJ, George JA, Surrena MA, Bishop C. Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat. J Neurochem. 2015;134(2):222\u2013232.2586628510.1111\/jnc.13125"},{"issue":"3","key":"b35","series-title":"J Cereb Blood Flow Metab","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/jcbfm.1995.63","article-title":"D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study","volume":"15","author":"Br\u00fccke T","year":"1995","unstructured":"Br\u00fccke T, W\u00f6ber C, Podreka I, W\u00f6ber-Bing\u00f6l C, Asenbaum S, Aull S,  D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study. J Cereb Blood Flow Metab. 1995;15(3):513\u2013518.771401010.1038\/jcbfm.1995.63"},{"issue":"4","key":"b36","series-title":"Synapse","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/(SICI)1098-2396(199804)28:4<280::AID-SYN3>3.0.CO;2-5","article-title":"Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates: evidence for tone-dependent normalization of striatal dopaminergic activity","volume":"28","author":"Tedroff J","year":"1998","unstructured":"Tedroff J, Torstenson R, Hartvig P, Sonesson C, Waters N, Carlsson A,  Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates: evidence for tone-dependent normalization of striatal dopaminergic activity. Synapse. 1998;28(4):280\u2013287.951783610.1002\/(SICI)1098-2396(199804)28:4<280::AID-SYN3>3.0.CO;2-5"},{"issue":"1","key":"b37","series-title":"Neuropsychopharmacology","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/npp.2010.81","article-title":"How placebos change the patient\u2019s brain","volume":"36","author":"Benedetti F","year":"2011","unstructured":"Benedetti F, Carlino E, Pollo A. How placebos change the patient\u2019s brain. Neuropsychopharmacology. 2011;36(1):339\u2013354.2059271710.1038\/npp.2010.81"},{"issue":"2","key":"b38","series-title":"Behav Brain Res","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0166-4328(02)00130-4","article-title":"Dopamine release in human ventral striatum and expectation of reward","volume":"136","author":"de la Fuente-Fern\u00e1ndez R","year":"2002","unstructured":"de la Fuente-Fern\u00e1ndez R, Phillips AG, Zamburlini M, Sossi V, Calne DB, Ruth TJ, Stoessl AJ. Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res. 2002;136(2):359\u2013363.1242939710.1016\/S0166-4328(02)00130-4"},{"issue":"13-14","key":"b39","series-title":"Brain Inj","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.3109\/02699052.2015.1073789","article-title":"Leisure and social participation in patients 4-10 years after aneurysmal subarachnoid haemorrhage","volume":"29","author":"Buunk AM","year":"2015","unstructured":"Buunk AM, Groen RJ, Veenstra WS, Spikman JM. Leisure and social participation in patients 4-10 years after aneurysmal subarachnoid haemorrhage. Brain Inj. 2015;29(13-14):1589\u20131596.2636268810.3109\/02699052.2015.1073789"}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/136\/6\/article-p1705.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/136\/6\/article-p1705.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/136\/6\/article-p1705.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:09:23Z","timestamp":1792804163000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/136\/6\/article-p1705.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":39,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.3171\/2021.7.jns211305","relation":{},"ISSN":["0022-3085","1933-0693"],"issn-type":[{"value":"0022-3085","type":"print"},{"value":"1933-0693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]}}}